PRENOXDIAZINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H27N3O
Molecular Weight	361.48
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(CC1=NC(CC(C2=CC=CC=C2)C3=CC=CC=C3)=NO1)N4CCCCC4

InChI

InChIKey=PXZDWASDNFWKSD-UHFFFAOYSA-N

InChI=1S/C23H27N3O/c1-4-10-19(11-5-1)21(20-12-6-2-7-13-20)18-22-24-23(27-25-22)14-17-26-15-8-3-9-16-26/h1-2,4-7,10-13,21H,3,8-9,14-18H2

HIDE SMILES / InChI

Molecular Formula	C23H27N3O
Molecular Weight	361.48
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/5968420 | https://www.ncbi.nlm.nih.gov/pubmed/2667194 | https://www.ncbi.nlm.nih.gov/pubmed/17300686

Prenoxdiazine under the brand name Libexin is used as an antitussive agent. It was shown, that the use of this drug for pregnant women with an unproductive cough could be beneficial.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
phagocytosis 3 Target ID: GO:0006909 Sources: https://www.ncbi.nlm.nih.gov/pubmed/340236	Activator 1430

PubMed

Title	Date	PubMed
[Study on the antitussive effect of Libexin in clinical practice].	1966 Jul 24	5968420
No teratogenic effect of prenoxdiazine: a population-based case-control study.	2007 Mar	17300686

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:49:07 GMT 2023` Edited by `admin` on `Fri Dec 15 15:49:07 GMT 2023`
Record UNII	S491HH391H
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PRENOXDIAZINE

Official Name

English

PRENOXDIAZINE [MI]

Common Name

English

1-(2-(3-(2,2-DIPHENYLETHYL)-1,2,4-OXADIAZOL-5-YL)ETHYL)PIPERIDINE

Systematic Name

English

prenoxdiazine [INN]

Common Name

English

PRENOXDIAZIN

Common Name

English

Prenoxdiazin [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

R05DB18